» Articles » PMID: 6215833

Mechanisms by Which Human Gliomas May Escape Cellular Immune Attack

Overview
Specialty Neurosurgery
Date 1982 Jan 1
PMID 6215833
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Whereas substantial evidence indicates that the majority of glioma patients make humoral immune responses to their own tumours, the evidence that glioma patients make significant cellular immune responses is more tenuous and controversial. In order to study those properties of human gliomas that might contribute to their ability to escape cell-mediated immune attack, we have examined the ability of cultured human glioma cells to elicit allogeneic cytolytic lymphocyte responses in vitro. Five of ten glioma lines were unable to elicit allogeneic cytolytic lymphocyte responses in mixed lymphocyte-tumour cultures, despite the presence of serologically detectable alloantigens on the surface of the glioma cells. Analysis of the reasons why certain glioma lines failed to stimulate cytolytic lymphocyte responses revealed three distinct mechanisms by which human gliomas may escape cellular immune attack: 1. a defect in immunogenicity which can be overcome by "help" from an allogeneic mixed lymphocyte reaction, 2. the secretion of a protective mucopolysaccharide coat, and 3. the production of macromolecular immunosuppressive substance(s). The implications of these findings for the immunotherapy of human gliomas are discussed.

Citing Articles

Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens.

Lokhov P, Balashova E J Cancer. 2010; 1:230-41.

PMID: 21151581 PMC: 3001283. DOI: 10.7150/jca.1.230.


Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.

Gomez G, Kruse C J Immunother. 2007; 30(3):261-73.

PMID: 17414317 PMC: 1894900. DOI: 10.1097/01.cji.0000211339.81211.25.


Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Gomez G, Kruse C Gene Ther Mol Biol. 2006; 10(A):133-146.

PMID: 16810329 PMC: 1474813.


The cancer stem cell: evidence for its origin as an injured autoreactive T cell.

Grandics P Mol Cancer. 2006; 5:6.

PMID: 16478542 PMC: 1386699. DOI: 10.1186/1476-4598-5-6.


Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme.

Schneider T, Gerhards R, Kirches E, Firsching R J Neurooncol. 2001; 53(1):39-46.

PMID: 11678429 DOI: 10.1023/a:1011856406683.


References
1.
Okada M, Klimpel G, Kuppers R, Henney C . The differentiation of cytotoxic T cells in vitro. I. Amplifying factor(s) in the primary response is Lyt 1 + cell dependent. J Immunol. 1979; 122(6):2527-33. View

2.
Lafferty K, Misko I, Cooley M . Allogeneic stimulation modulates the in vitro response of T cells to transplantation antigen. Nature. 1974; 249(454):275-6. DOI: 10.1038/249275a0. View

3.
Coakham H, KORNBLITH P, Quindlen E, POLLOCK L, Wood W, Hartnett L . Autologous humoral response to human gliomas and analysis of certain cell surface antigens: in vitro study with the use of microcytotoxicity and immune adherence assays. J Natl Cancer Inst. 1980; 64(2):223-33. DOI: 10.1093/jnci/64.2.223. View

4.
Young H, Sakalas R, Kaplan A . Inhibition of cell-mediated immunity in patients with brain tumors. Surg Neurol. 1976; 5(1):19-23. View

5.
Boyum A . Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968; 97:77-89. View